Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 13/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.43 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.43 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29226728 | 0.90 | MTNR1A (0.45) | MTNR1BMTNR1ADRD2GAASMN1; SMN2 | |
| SCHEMBL496918 | 0.84 | SLC9A1 (0.43) | MTNR1BMTNR1ASLC9A1SLC9A5SLC9A2 | |
| SCHEMBL4104704 | 0.83 | DRD2 (0.37) | MTNR1BMTNR1ADRD2GAASMN1; SMN2 | |
| SCHEMBL10005787 | 0.82 | MTNR1B (0.39) | MTNR1BMTNR1ASLC9A1SLC9A5SLC9A2 | |
| SCHEMBL30184316 | 0.82 | PARP1 (0.57) | MTNR1BMTNR1ASLC9A1SLC9A5SLC9A2 | |
| SCHEMBL7122066 | 0.82 | PARP1 (0.57) | MTNR1BMTNR1ASLC9A1SLC9A5SLC9A2 | |
| SCHEMBL30884588 | 0.81 | ALDH1A1 (0.46) | MTNR1BMTNR1ASMN1; SMN2KDM4E | |
| SCHEMBL28775369 | 0.81 | ALDH1A1 (0.46) | MTNR1BMTNR1ASMN1; SMN2KDM4E | |
| SCHEMBL29133954 | 0.81 | MTNR1B (0.46) | MTNR1BMTNR1ASLC9A1SLC9A5SLC9A2 | |
| SCHEMBL30184412 | 0.81 | MTNR1B (0.46) | MTNR1BMTNR1ASLC9A1SLC9A5SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011528012-A | — | — | 2011-11-10 | — | — | JP | claimed |
| EP-2328882-A1 | SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK Pharmaceuticals d.d. (SI) | 2011-06-08 | — | — | EP | claimed |
| WO-2010007022-A1 | SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-01-21 | — | — | WO | claimed |
| CN-113402490-B | Preparation method of 1,2,6, 7-tetrahydro-8H-indeno [5,4-b ] furan-8-one | 白银京宇新药业有限公司 | 2023-01-03 | — | — | CN | disclosed |
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2243775-A1 | Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon | LEK Pharmaceuticals d.d. (SI) | 2010-10-27 | — | — | EP | disclosed |
| EP-2243775-A1 | Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon | LEK Pharmaceuticals d.d. (SI) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010115897-A2 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115897-A2 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115897-A2 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115897-A2 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010092107-A1 | SYNTHESIS OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO-[5,4-B]FURAN-8-YL)ETHYL]PROPIONAMIDE | LEK PHARMACEUTICALS D.D. (SI) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010007022-A1 | SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007022-A1 | SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | RTN3, CYCS, ATL3 | MTNR1B 2199/4885MTNR1A 2367/4885DRD2 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.